Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
No Result
View All Result

Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu

Daily Remedy by Daily Remedy
September 10, 2021
in
0

Moderna plans to announce the development of a vaccine candidate that will protect against Covid-19 and the flu, to be known as mRNA-1073. The company will also announce a pediatric vaccine called mRNA-1365, which combines its experimental respiratory syncytial virus vaccine with its experimental human metapneumovirus vaccine.

The news came less than an hour before the company begins an investor event intended to discuss the company’s clinical development pipeline. Top Moderna (ticker: MRNA) executives, including CEO Stéphane Bancel, newly appointed chief medical officer Dr. Paul Burton, and the company’s president, Dr. Stephen Hoge, were due to appear.

Source: Barrons

https://www.barrons.com/articles/moderna-stock-covid-flu-vaccine-51631189754

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

summary An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients. Chapters 00:00 Understanding Drug Pricing Dynamics 03:52 Exploring the Drug Pricing Database 10:07 Patient Advocacy and Drug Pricing 13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

No Result
View All Result

© 2026 Daily Remedy